FI116121B - Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi - Google Patents

Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi Download PDF

Info

Publication number: FI116121B
Authority: FI; Finland
Prior art keywords: lhrh; cetrorelix; peptide; particle size; analog
Prior art date: 1993-12-09

Application number

FI962354A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI962354L (fi

FI962354A0 (fi

Inventor

Juergen Engel

Peter Hilgard

Karin Klokkers-Bethke

Thomas Reissmann

Original Assignee

Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-09

Filing date

1996-06-06

Publication date

2005-09-30

1996-06-06 Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh

1996-06-06 Publication of FI962354L publication Critical patent/FI962354L/fi

1996-06-06 Publication of FI962354A0 publication Critical patent/FI962354A0/fi

1996-06-10 Priority claimed from US08/661,017 external-priority patent/US5773032A/en

2005-09-30 Application granted granted Critical

2005-09-30 Publication of FI116121B publication Critical patent/FI116121B/fi

Links

XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 title claims abstract description 21
150000003839 salts Chemical class 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims description 34
239000000203 mixture Substances 0.000 title claims description 24
230000008569 process Effects 0.000 title claims description 20
239000002434 gonadorelin derivative Substances 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 26
108700008462 cetrorelix Proteins 0.000 claims description 15
239000002244 precipitate Substances 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 11
239000002245 particle Substances 0.000 claims description 11
229960003230 cetrorelix Drugs 0.000 claims description 10
229950005627 embonate Drugs 0.000 claims description 10
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 6
102100024028 Progonadoliberin-1 Human genes 0.000 claims description 6
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
229920002988 biodegradable polymer Polymers 0.000 claims description 5
239000004621 biodegradable polymer Substances 0.000 claims description 5
239000003925 fat Substances 0.000 claims description 4
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 3
-1 genirelix Chemical compound 0.000 claims description 3
238000002441 X-ray diffraction Methods 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 2
108010083551 iturelix Proteins 0.000 claims description 2
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 3
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims 1
108010070670 antarelix Proteins 0.000 claims 1
238000001291 vacuum drying Methods 0.000 claims 1
239000012730 sustained-release form Substances 0.000 abstract description 12
230000000694 effects Effects 0.000 abstract description 11
238000013268 sustained release Methods 0.000 abstract description 9
UCANQOXFIYWYIX-IDEADWEOSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid Chemical compound OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O UCANQOXFIYWYIX-IDEADWEOSA-N 0.000 abstract description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 20
239000013543 active substance Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical group CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 13
239000000243 solution Substances 0.000 description 13
239000003814 drug Substances 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 11
229940079593 drug Drugs 0.000 description 11
229960003604 testosterone Drugs 0.000 description 10
230000009471 action Effects 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
108010069236 Goserelin Proteins 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
229920001577 copolymer Polymers 0.000 description 7
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 6
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
229960001865 cetrorelix acetate Drugs 0.000 description 5
108010037003 Buserelin Proteins 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
108010050144 Triptorelin Pamoate Proteins 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
229960002913 goserelin Drugs 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 4
229960004338 leuprorelin Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 4
108010000817 Leuprolide Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000711 cancerogenic effect Effects 0.000 description 3
231100000315 carcinogenic Toxicity 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000003163 gonadal steroid hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000126 substance Substances 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
YXEGKKOWBPNNEY-UHFFFAOYSA-N acetic acid;naphthalene Chemical compound CC(O)=O.C1=CC=CC2=CC=CC=C21 YXEGKKOWBPNNEY-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
229960002719 buserelin Drugs 0.000 description 2
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 2
229960005064 buserelin acetate Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
229940100662 nasal drops Drugs 0.000 description 2
238000002559 palpation Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
229960004824 triptorelin Drugs 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
229940033942 zoladex Drugs 0.000 description 2
XHCGTVHIQUXPRM-SSIREWOPSA-N (2s)-n-[(2r,4s,7r)-7-acetamido-2-amino-4-[[(2s)-2-amino-6-[(5-amino-1h-1,2,4-triazol-3-yl)amino]hexanoyl]-[(2s)-2-[[(2r)-2-amino-6-[(5-amino-1h-1,2,4-triazol-3-yl)amino]hexanoyl]amino]-4-methylpentanoyl]carbamoyl]-1-(4-chlorophenyl)-8-naphthalen-2-yl-3,6- Chemical compound C([C@@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N(C(=O)[C@@H](N)CCCCNC=1N=C(N)NN=1)C(=O)[C@@](CC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)(N(C(=O)[C@H](CO)NC(=O)[C@H](N)CC=1C=NC=CC=1)C(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCCNC(C)C)C(=O)[C@H](N)CC=1C=CC(Cl)=CC=1)CCCNC1=NNC(N)=N1 XHCGTVHIQUXPRM-SSIREWOPSA-N 0.000 description 1
AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 1
BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000013585 Bombesin Human genes 0.000 description 1
108010051479 Bombesin Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000005605 Hormone-Dependent Neoplasms Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
URBHJJGWUIXBFJ-UHFFFAOYSA-N [C].[Cl] Chemical compound [C].[Cl] URBHJJGWUIXBFJ-UHFFFAOYSA-N 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000006053 animal diet Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
108700022499 azaline Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229950002475 mesilate Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
235000015927 pasta Nutrition 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Peptides Or Proteins (AREA)

FI962354A 1993-12-09 1996-06-06 Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi FI116121B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DE4342092		1993-12-09
DE4342092A DE4342092B4 (de)	1993-12-09	1993-12-09	Langwirkende Injektionssuspension und Verfahren zur Herstellung
PCT/EP1994/003904 WO1995015767A1 (en)	1993-12-09	1994-11-25	Long-acting injection suspensions and a process for their preparation
EP9403904		1994-11-25
US66101796		1996-06-10
US08/661,017 US5773032A (en)	1993-12-09	1996-06-10	Long-acting injection suspensions and a process for their preparation

Publications (3)

Publication Number	Publication Date
FI962354L FI962354L (fi)	1996-06-06
FI962354A0 FI962354A0 (fi)	1996-06-06
FI116121B true FI116121B (fi)	2005-09-30

Family

ID=25931926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI962354A FI116121B (fi)	1993-12-09	1996-06-06	Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi

Country Status (26)

Country	Link
EP (1)	EP0732934B1 (de)
JP (1)	JPH09509145A (de)
CN (2)	CN1136916C (de)
AT (1)	ATE310530T1 (de)
AU (1)	AU677748B2 (de)
BR (1)	BR9408272A (de)
CZ (1)	CZ291025B6 (de)
DE (1)	DE4342092B4 (de)
DK (1)	DK0732934T3 (de)
EE (1)	EE03224B1 (de)
EG (1)	EG20787A (de)
ES (1)	ES2251715T3 (de)
FI (1)	FI116121B (de)
HR (1)	HRP940978B1 (de)
HU (1)	HU217081B (de)
IL (1)	IL111928A (de)
LV (1)	LV11596B (de)
NO (1)	NO318984B1 (de)
NZ (1)	NZ277239A (de)
PL (1)	PL186929B1 (de)
RO (1)	RO119343B1 (de)
RS (1)	RS49511B (de)
RU (1)	RU2152222C1 (de)
SK (2)	SK284980B6 (de)
WO (1)	WO1995015767A1 (de)
ZA (1)	ZA949798B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
DE69434553T2 (de) *	1993-12-09	2006-08-10	Zentaris Gmbh	Lang wirkende injektionssuspensionen von lhrh-analogen und ein verfahren für ihre herstellung
WO1998032423A1 (en) *	1997-01-29	1998-07-30	Takeda Chemical Industries, Ltd.	Sustained-release microspheres, their production and use
DE10040700A1 (de) *	2000-08-17	2002-02-28	Asta Medica Ag	Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
AU2002221139A1 (en) *	2000-12-15	2002-06-24	Takeda Chemical Industries Ltd.	Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TW200526267A (en)	2001-06-29	2005-08-16	Takeda Chemical Industries Ltd	Controlled release composition and method of producing the same
US7098305B2 (en) *	2001-09-06	2006-08-29	Ardana Bioscience Limited	Sustained release of microcrystalline peptide suspensions
EP1674082A1 (de)	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
AR064381A1 (es)	2006-12-18	2009-04-01	Takeda Pharmaceutical	Composicion de liberacion sostenida y metodos para producirla
WO2011060352A1 (en)	2009-11-16	2011-05-19	Ipsen Pharma S.A.S.	Pharmaceutical compositions of melanocortin receptor ligands
CN102504018A (zh) *	2011-10-28	2012-06-20	沈阳药科大学	可持续释放的蜂毒肽帕莫酸盐及其制剂
CN109311832B (zh) *	2016-03-29	2023-01-06	上海华汇拓医药科技有限公司	沃替西汀的帕莫酸盐及其晶型
CN108969478A (zh) *	2018-08-29	2018-12-11	江南大学	一种美金刚难溶盐缓释注射剂及其制备方法
CN110003195B (zh) *	2019-05-21	2020-05-26	湖北中医药大学	鲁拉西酮晶体及其制备方法和在注射给药系统中的应用
CN112569340A (zh) *	2020-12-31	2021-03-30	苏州素仕生物科技有限公司	一种无菌布舍瑞林注射液及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3852422A (en) *	1971-06-26	1974-12-03	Serono Ist Farm	Long-active gonadotropins
NZ181036A (en) *	1975-06-12	1978-12-18	A Schally	Luteinising hormone releasing hormone analogues and intermediates therefor
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
FR2647677B1 (fr) *	1989-05-31	1991-09-27	Roussel Uclaf	Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
CH679207A5 (de) *	1989-07-28	1992-01-15	Debiopharm Sa
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.

1993
- 1993-12-09 DE DE4342092A patent/DE4342092B4/de not_active Expired - Fee Related
1994
- 1994-11-25 CN CNB941944050A patent/CN1136916C/zh not_active Expired - Fee Related
- 1994-11-25 RO RO96-01143A patent/RO119343B1/ro unknown
- 1994-11-25 HU HU9601584A patent/HU217081B/hu not_active IP Right Cessation
- 1994-11-25 EP EP95903282A patent/EP0732934B1/de not_active Expired - Lifetime
- 1994-11-25 NZ NZ277239A patent/NZ277239A/en not_active IP Right Cessation
- 1994-11-25 ES ES95903282T patent/ES2251715T3/es not_active Expired - Lifetime
- 1994-11-25 PL PL94314913A patent/PL186929B1/pl not_active IP Right Cessation
- 1994-11-25 AU AU12199/95A patent/AU677748B2/en not_active Ceased
- 1994-11-25 SK SK667-96A patent/SK284980B6/sk not_active IP Right Cessation
- 1994-11-25 JP JP7515921A patent/JPH09509145A/ja not_active Ceased
- 1994-11-25 CN CNB021593949A patent/CN1248732C/zh not_active Expired - Fee Related
- 1994-11-25 AT AT95903282T patent/ATE310530T1/de not_active IP Right Cessation
- 1994-11-25 BR BR9408272A patent/BR9408272A/pt not_active Application Discontinuation
- 1994-11-25 WO PCT/EP1994/003904 patent/WO1995015767A1/en not_active Ceased
- 1994-11-25 EE EE9600061A patent/EE03224B1/xx not_active IP Right Cessation
- 1994-11-25 DK DK95903282T patent/DK0732934T3/da active
- 1994-11-25 CZ CZ19961420A patent/CZ291025B6/cs not_active IP Right Cessation
- 1994-11-25 SK SK5090-2005A patent/SK284981B6/sk not_active IP Right Cessation
- 1994-11-25 RU RU96115021/14A patent/RU2152222C1/ru not_active IP Right Cessation
- 1994-12-07 EG EG77194A patent/EG20787A/xx active
- 1994-12-08 RS YU72194A patent/RS49511B/sr unknown
- 1994-12-08 IL IL11192894A patent/IL111928A/xx not_active IP Right Cessation
- 1994-12-08 HR HR940978A patent/HRP940978B1/xx not_active IP Right Cessation
- 1994-12-08 ZA ZA949798A patent/ZA949798B/xx unknown
1996
- 1996-05-09 NO NO19961877A patent/NO318984B1/no not_active IP Right Cessation
- 1996-06-06 FI FI962354A patent/FI116121B/fi not_active IP Right Cessation
- 1996-07-09 LV LVP-96-226A patent/LV11596B/en unknown

Also Published As

Publication number	Publication date
HU9601584D0 (en)	1996-08-28
ES2251715T3 (es)	2006-05-01
IL111928A (en)	1999-11-30
PL314913A1 (en)	1996-09-30
HUT75712A (en)	1997-05-28
HRP940978A2 (en)	1997-02-28
DE4342092B4 (de)	2007-01-11
AU1219995A (en)	1995-06-27
YU72194A (sh)	1997-03-07
FI962354L (fi)	1996-06-06
EE03224B1 (et)	1999-10-15
CN1248732C (zh)	2006-04-05
SK284980B6 (sk)	2006-03-02
RS49511B (sr)	2006-10-27
CN1494919A (zh)	2004-05-12
FI962354A0 (fi)	1996-06-06
JPH09509145A (ja)	1997-09-16
NO961877D0 (no)	1996-05-09
HK1063746A1 (en)	2005-01-14
AU677748B2 (en)	1997-05-01
WO1995015767A1 (en)	1995-06-15
NZ277239A (en)	1997-03-24
ATE310530T1 (de)	2005-12-15
CZ291025B6 (cs)	2002-12-11
BR9408272A (pt)	1996-12-17
RU2152222C1 (ru)	2000-07-10
RO119343B1 (ro)	2004-08-30
ZA949798B (en)	1995-08-18
LV11596A (lv)	1996-12-20
SK66796A3 (en)	1997-08-06
CZ142096A3 (en)	1996-12-11
PL186929B1 (pl)	2004-04-30
CN1136916C (zh)	2004-02-04
LV11596B (en)	1997-06-20
HRP940978B1 (en)	2006-08-31
DE4342092A1 (de)	1995-06-14
NO961877L (no)	1996-05-09
DK0732934T3 (da)	2006-03-27
SK284981B6 (sk)	2006-03-02
EG20787A (en)	2000-02-29
EP0732934A1 (de)	1996-09-25
CN1136779A (zh)	1996-11-27
IL111928A0 (en)	1995-03-15
EP0732934B1 (de)	2005-11-23
NO318984B1 (no)	2005-05-30
HU217081B (hu)	1999-11-29

Publication	Publication Date	Title
FI116121B (fi)	2005-09-30	Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi
FI116196B (fi)	2005-10-14	Menetelmä jatkuvasti vapauttavan valmisteen tuottamiseksi
US5773032A (en)	1998-06-30	Long-acting injection suspensions and a process for their preparation
AU2018338924B2 (en)	2020-05-21	Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same
AU770460B2 (en)	2004-02-19	Methods for detecting lesions in dense breast tissue using LHRH antagonists
KR100344330B1 (ko)	2002-11-30	지속성주사현탁제
EP3785734B1 (de)	2023-04-12	Langwirkendes fettsäurebindendes gnrh-derivat und dieses enthaltende pharmazeutische zusammensetzung
HK1063746B (en)	2006-09-01	Long-acting injection suspensions and a process for their preparation

Legal Events

Date	Code	Title	Description
2005-09-30	FG	Patent granted	Ref document number: 116121 Country of ref document: FI
2011-07-08	MM	Patent lapsed

Date

Code

Title

Description